A b s t r a c t
Protein S (gene symbol, PROS1; GeneID, 5627; MIM No. 176880) was first described in 1979 by DiScipio and Davie 1 as a glycoprotein containing γ-carboxylated glutamic acid residues similar to other proteins involved in coagulation processes. In contrast with other vitamin K-dependent clotting factors, protein S, which was named after the place of its first isolation, Seattle, WA, lacks serine protease activity. Further studies demonstrated that it has cofactor function for activated protein C. Under normal conditions, more than 60% of protein S is bound to the C4b binding protein, and unbound protein S is available to form a complex with activated protein C in the presence of phospholipids and calcium ions. This complex irreversibly inactivates factors Va and VIIIa by proteolysis, thus interfering with the formation of the prothrombinase and tenase complexes on procoagulant surfaces. Thrombin inactivates protein S by proteolytic cleavage.
Two highly homologous genes are located near the centromeric region of chromosome 3, at 3p11.1-3q11.2: one is the active, encoding gene PROS1, and the other, PROS2 or PROSP, is, in all likelihood, a pseudogene with no open reading frame. PROS2 lacks exon 1, which contains the translational start site and encodes for a signal peptide. Furthermore, there are several destructive mutations contained in PROS2. 2 Owing to the cofactor function of protein S, the laboratory phenotype is difficult to assess. Typically, measurement is performed using a latex ligand immunoassay for the determination of free antigen and using clotting assays that detect protein S-mediated enhancement of the anticoagulant function of activated protein C. In addition to congenital deficiencies, there are numerous physiologic and pathologic conditions that lead to decreased protein S levels. Inflammation leads to increased Upon completion of this activity you will be able to:
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C4b binding protein levels and concomitantly decreases the levels of unbound and functional protein S. Pregnancy and hepatic disorders, such as hepatitis and cirrhosis, and treatment with hormonal contraceptives 3 and the lingering effect of previous anticoagulation similarly lead to decreased levels.
Materials and Methods

Patients
From 2005 to 2010, 5,851 patients with thrombophilia or the suspicion of an inherited thrombophilia attended the hemostasis outpatient clinics of the University of Munich, Munich, Germany, for diagnostic studies. The suspicion of familial protein S deficiency was raised in 170 cases, and the patients were registered into a database. Of these, 135 patients consented to molecular analysis of the PROS1 gene. All patients came from a Caucasian background. In addition to assessments of the concentration of the free antigen, protein S activity, and prothrombin time, several other patient characteristics were collected, including medical history, family history, other explaining risk factors (factor V Leiden and prothrombin G20210A mutant, antiphospholipid antibodies), and other causes of acquired protein S deficiencies (pregnancy, hormonal contraception, chronic systemic inflammation).
Protein S Assays
The measurement of protein S was performed by the determination of free antigen and by measuring protein S activity. Free protein S was quantified using the HemosIL Free Protein S latex ligand immunoassay 4 (Instrumentation Laboratory SpA, Milan, Italy). Protein S activity was measured using the STA Protein S Clotting assay (Diagnostica Stago, Asnières, France). 5 This clotting assay detects protein S activity as the enhancement of protein C activity in a system enriched for factor Va, resulting in a prolonged clotting time.
PROS1 Gene Analysis
Following the protocol proposed by Ten Kate et al, 6 all 15 exons of the PROS1 gene were screened for PROS1 sequence variants by direct sequencing. In addition, multiplex ligationdependent probe amplification (MLPA) 7 was performed to detect target sequence copy number changes in cases in which no mutation was detected by direct sequencing and repeatedly low protein S values suggested a genetically determined deficiency. For MLPA, we used the SALSA KIT P112 PROS1 from MRC-Holland, Amsterdam, the Netherlands. 8 In contrast with DNA sequencing, MLPA focuses on copy number changes. Before exponential amplification by polymerase chain reaction (PCR), the MLPA probes hybridize with adjacent regions of the DNA and are ligated using a thermostable ligase. Subsequently, PCR is used to amplify the original probes, and copy number changes are evaluated by electrophoresis by comparing the relative amounts of the products. The probe mix used for the detection of deletions in the PROS1 gene contained probes for 12 of 15 PROS1 exons. Deletions in exons 3, 8, and 14 could not be detected with this MLPA system. Two probes were present for exon 1, and one probe each for a short distance 5' of the PROS1 promoter and for the PROS pseudogene were included. In addition, 16 reference probes that detect several different autosomal chromosomal locations were included in the probe mix. Heterozygous deletions of recognition sequences were expected to produce a 35% to 50% reduced relative peak area for the amplification product of that probe.
Results
PROS1 gene analysis was performed in 135 patients with suspected protein S deficiency ❚Table 1❚. There were 85 patients with venous thromboembolism (VTE). In this group, 46 patients were determined to have plasma protein S activity levels lower than 60%, and the corresponding mutations were found in 28 of them (17 unrelated relatives, and 1 family with 3 members). The remaining 39 patients with VTE were receiving oral anticoagulation (n = 27) or had borderline values but had family or medical histories that suggested protein S deficiency (n = 12). In 8 of these cases, mutations in the PROS1 gene were identified. Because of pathologic protein S levels or familial protein S deficiency, 31 patients who themselves had no pathology but did have VTE in their family histories were genetically examined. A total of 10 patients (2 unrelated persons and 4 couples of relatives) had mutations in the PROS1 gene. A separate group of 9 patients had a history of cerebrovascular infarction or repeated transient ischemic attacks. One patient with low protein S activity was revealed to have a corresponding mutation in the PROS1 gene. One patient had recurrent abortion and borderline values for protein S, but no mutation could be verified. Finally, 2 cases from a group of 9 patients who had no clinical manifestations in their own or their family histories and who were referred to us because of low protein S levels showed mutations in the PROS1 gene.
Laboratory Phenotype of Protein S Deficiency
The following phenotypic analysis excluded patients receiving vitamin K antagonist treatment, patients who were pregnant or receiving hormonal contraceptives, and patients with other causes of acquired protein S deficiency. ❚Figure 1❚ shows the protein S activity levels of the remaining 82 patients, grouped according to results of genetic analysis.
There were significant differences in the levels of residual activity when grouped by the type of mutation. Patients without mutations detectable by the test system typically showed protein S activity levels more than 40%. One case in which mutations were not detectable showed persistently low levels. Whether a deletion existed in exons 3, 8, and 14 in this case could not be examined. Nonsense mutations and large deletions were linked to the strongest reduction of the level of activity. The 2 missense mutations that did not show pathologic activities were the previously unknown polymorphisms c.1016T>A and c.1138A>C. The mean values and SDs are shown in ❚Table 2❚.
Free antigen levels of protein S are depicted in ❚Figure 2❚ according to the type of mutation. Table 3 .
❚Table 4❚, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] normal and pathologic findings for free antigen levels in different patients with the same mutation are not unusual. Similar to measurement of activity nonsense mutations and large deletions were linked to the strongest reduction of free antigen concentration.
Genetic Background of Protein S Deficiency
By using sequence analysis and multiplex ligationdependent probe amplification, we identified mutations in 49 patients from 35 families. We were able to genetically characterize 7 new and 8 previously described missense mutations with amino acid exchanges, 2 unknown and 1 previously described base pair exchanges resulting in a stop codon, 3 unknown frame shift mutations, and 4 new and 1 previously known splice site mutations. Large deletions were identified by MLPA in 4 families. In 1 family, we characterized a previously unknown deletion of exon 9 and the bordering intron regions (Table 4) .
Discussion
The purpose of our study was to assess genotypes and laboratory and clinical phenotypes in patients with hereditary protein S deficiency. During 5 years, in our collection of 5,851 single cases that were referred to our hemostasis outpatient clinics because of their own or familial thrombophilia, suspicion of protein S deficiency arose in 170 patients. Of these, 135 were examined genetically, and mutations were identified in 49. Although the database included laboratory and clinical parameters, the total significance of protein S deficiency in our collection can only be estimated owing to vitamin K antagonist intake. Owing to the prevalence of oral anticoagulants, protein S deficiency as a cause for thrombophilia is presumably underdiagnosed. The prevalence of familial protein S deficiency was estimated to be between 0.03% and 0.13% by Dykes et al 18 in a Scottish study that examined 3,788 healthy volunteers. Others have presumed higher frequencies of approximately 2% in the general population 19 and 1% to 13% in patients with thrombosis. 20 The clinical phenotype of symptomatic protein S deficiency is recurrent deep vein thrombosis and pulmonary embolism. Case reports have suggested an association with warfarin necrosis. 21 There is no clear evidence for protein S deficiency being a risk factor for arterial infarction, eg, cerebral insult, even in the case of patent foramen ovale. [22] [23] [24] In approximately half of the cases with VTE, the event is unprovoked and is not preceded by a risk situation, such as air travel, hormonal contraception or replacement therapy, pregnancy or puerperium, immobilization, surgery, or trauma. 25 However, in a prospective cohort study by Sanson et al 26 with 70 asymptomatic carriers of a protein S deficiency, the annual incidence of an initiating thromboembolic event seemed to be 0.4% per year. In comparison, antithrombin and protein C deficiency showed yearly incidence rates of 1.6% and 1.0%, respectively, in the same study.
Because venous thromboembolic events in the patient or family history are typically the features that lead to referral to our hemostasis outpatient clinics, a selection bias should exist in our collection. Therefore, a comparison between different groups within this collection would be uninformative. Our results show, however, that in patients with borderline results for coagulation testing, anamnesis for VTE is crucial for the assessment of pretest probability of mutational analysis.
Following the analysis of the data for 135 patients for whom the suspicion of protein S deficiency had been raised and who consented to genetic testing, there remained only 1 case with protein S activity values less than 40% that could not be explained by mutation or deletion in the PROS1 gene using this test system. Whether in this case with known severe familial protein S deficiency a single deletion in the unscreened exons 3, 8, and 14 exists or whether in rare cases other genetic defects can lead to that phenotype is unclear. Thus, our findings support the observation by Mulder et al 27 that low cutoff values increase the diagnostic performance of protein S assays.
For a long time, the observation of patients with a consistent history of familial protein S deficiency and no pathologic finding in PROS1 sequence analysis has puzzled the experts. However, gene linkage analysis by Lanke et al 28 revealed an association with the locus of PROS1. Johansson et al 17 detected large deletions in the PROS1 gene in 3 of 8 families studied by using quantitative PCR. The introduction of MLPA simplified the detection of large deletions within the genome. By this method, Pintao et al 8 found large deletions of the PROS1 gene in 6 of 18 patients with protein S deficiency who were negative for sequence variants. In our patient collection, large deletions were found in 6 patients from 4 different families. As mentioned, there remained only 1 case with activity levels lower than 40% that could not be explained by sequence variation or deletion in the PROS1 gene. Therefore, we affirm the statement that large deletions are a common finding in patients who test negatively for PROS1 sequence variations and who have consistently low levels of protein S.
The phenotypic expression of protein S deficiency has conventionally been described as 1 of 3 types. A lack of free protein and activity is classified as type I. Patients with type II deficiency have normal levels of free antigen but diminished activity, and this type is usually attributed to missense mutations. 29 Type III has been described as normal total protein levels but reduced free protein and, hence, reduced activity. However, it could not be shown that type III deficiency has a causative effect on thrombosis. 30 As changes from one type to another are observable not only in different persons in the same family but also in the same person at different times, this classification is questionable. One reason for these changes might be that testing in hemostasis is prone to comparatively high interassay, batch-to-batch, and day-to-day variability such that these fluctuations may obscure existing differences between selected groups. Furthermore, the heterogeneity of PROS1 mutations contradicts the notion of accurately defined states of deficiency. In our opinion, the laboratory phenotype of protein S deficiency is a continual decrease in activity and free antigen, and this decrease can show great differences not only between patients with the same mutation but also at different times in the same person. However, from our results, we can assert a clear decrease in protein and activity levels in the genetically defined categories ranging from borderline values in patients in whom no genetic changes were observable to missense and nonsense mutations to repeatedly low values in patients with large deletions.
With regard to the many difficulties the diagnosis of protein S deficiency implies, Marlar and Gausman 31 recently proposed a diagnostic algorithm for the assessment of protein S abnormalities. We agree with the points that the evaluation of the pretest probability is the most important item and that, ideally, tests with pathologic results should be repeated after 4 to 6 weeks. However, we challenge the point that the measurement of free antigen concentrations should precede activity testing as a criterion for inclusion in further testing. There are not enough data to show that antigen binding is more sensitive than coagulation tests for protein S deficiency. As protein S activity reflects the function of the protein, we consider its measurement also necessary for exclusion of protein S deficiency.
